US Q4 2019 earnings season starts decently well.

After 9% of the US results are out, both median yearly growth and surprises vs consensus look decent. Historically, this bodes well for the rest of the season.

  • Market Commentary

Highlights:

  • After 9% of the US results are out, both median yearly growth and surprises vs consensus look decent. Historically, this bodes well for the rest of the season.
  • Earnings growth consensus for Q4 2019 has been declining to become slightly negative: from 11.5% one year ago to -0.5% yoy. Consensus for sales (+4.3% yoy) remained broadly stable.
  • A weaker trade-weighted US dollar, higher oil prices, bottoming capacity utilization and recovering margin proxy (CPI/unit labor costs) all signal earnings to have a mid-single digit growth this year.
  • This would also be facilitated through base effects as earnings growth in 2019 was flat.
  • In the euro area (EA), increased credit impulse, better IFO momentum, slowing labor costs increase and better macro surprises are also pointing to a bottoming earnings momentum, provided that exogenous risks stay at bay, as we expect.
  • We maintain OW on equities, albeit with a reduced exposure after the recent rally.

Download the full publication below

US Q4 2019 EARNINGS
SEASON STARTS
DECENTLY WELL.
DOWNLOAD
PDF
MORE INSIGHTS

RELATED INSIGHTS

READ NOW
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
READ NOW
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
READ NOW
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
MORE INSIGHTS